Published in Cancer Treat Rev on March 11, 2010
Personalized Treatment Selection for Metastatic Breast Cancer | NCT00780676
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer | NCT00570700
Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients | NCT00817531
Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology (2011) 1.64
A phase 2 trial of dasatinib in advanced melanoma. Cancer (2010) 1.40
Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer (2011) 1.34
Metastatic bone disease: role of transcription factors and future targets. Bone (2010) 1.30
Cancer metastases: challenges and opportunities. Acta Pharm Sin B (2015) 1.22
Role of estrogen receptor signaling in breast cancer metastasis. Int J Breast Cancer (2011) 1.06
Genetics of glioblastoma: a window into its imaging and histopathologic variability. Radiographics (2011) 1.06
Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells. J Mol Signal (2011) 1.05
Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF. Oncogene (2013) 0.97
Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Rev Endocrinol Metab (2011) 0.96
Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells. Clin Exp Metastasis (2011) 0.93
Activation of rapid oestrogen signalling in aggressive human breast cancers. EMBO Mol Med (2012) 0.91
Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen. PLoS One (2012) 0.91
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2012) 0.88
Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter. Int J Cancer (2012) 0.88
Drosophila Abelson kinase mediates cell invasion and proliferation through two distinct MAPK pathways. Oncogene (2010) 0.88
The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells. PLoS One (2011) 0.87
Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. Clin Cancer Res (2011) 0.87
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Invest New Drugs (2012) 0.87
Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data. Clin Investig (Lond) (2011) 0.86
The CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer. J Transl Med (2012) 0.86
Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells. Int J Oncol (2014) 0.85
Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma. Oncotarget (2015) 0.84
Genome-wide analysis of three-way interplay among gene expression, cancer cell invasion and anti-cancer compound sensitivity. BMC Med (2013) 0.83
Proteolysis of EphA2 Converts It from a Tumor Suppressor to an Oncoprotein. Cancer Res (2015) 0.83
Data-driven modeling of SRC control on the mitochondrial pathway of apoptosis: implication for anticancer therapy optimization. PLoS Comput Biol (2013) 0.81
Breast cancer at bone metastatic sites: recent discoveries and treatment targets. J Cell Commun Signal (2011) 0.81
Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy. Biomaterials (2015) 0.80
SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment. PLoS One (2015) 0.80
Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. Br J Cancer (2015) 0.80
Src inhibitors in suppression of papillary thyroid carcinoma growth. Head Neck (2013) 0.80
SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis. Cancer Res (2014) 0.79
A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme. Oncotarget (2015) 0.79
Role of retinoic acid and platelet-derived growth factor receptor cross talk in the regulation of neonatal gonocyte and embryonal carcinoma cell differentiation. Endocrinology (2015) 0.79
Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression. Int J Gynecol Cancer (2014) 0.78
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. Cancer (2016) 0.77
Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src. Oncotarget (2016) 0.77
Phosphorylation of TOPK at Y74, Y272 by Src increases the stability of TOPK and promotes tumorigenesis of colon. Oncotarget (2016) 0.77
Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients. Cancer Cell (2016) 0.77
Global phosphotyrosine proteomics identifies PKCδ as a marker of responsiveness to Src inhibition in colorectal cancer. PLoS One (2013) 0.76
Improved angiostatic activity of dasatinib by modulation with hydrophobic chains. ACS Med Chem Lett (2015) 0.76
Therapeutic advances in women's cancers. Front Biosci (Schol Ed) (2011) 0.76
Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat (2016) 0.76
Expression and function of MutT homolog 1 in distinct subtypes of breast cancer. Oncol Lett (2017) 0.75
Role of estrogen receptors and Src signaling in mechanisms of bone metastasis by estrogen receptor positive breast cancers. J Transl Med (2017) 0.75
The ETS family of oncogenic transcription factors in solid tumours. Nat Rev Cancer (2017) 0.75
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell (1991) 14.89
Mechanisms of bone metastasis. N Engl J Med (2004) 10.40
Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol (1995) 9.03
The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood (2004) 6.92
Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell (2009) 5.24
Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol (2008) 3.95
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat (2007) 3.83
Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest (1992) 3.40
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res (2005) 3.08
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res (2007) 2.94
Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res (2007) 2.84
Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res (2005) 2.76
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol (2008) 2.75
Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res (2006) 2.65
Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res (2008) 2.59
Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res (2004) 2.56
Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res (2006) 2.41
Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther (2009) 2.37
Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest (1993) 2.29
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol (2006) 2.07
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.99
Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res (2007) 1.96
Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene (2001) 1.89
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res (2008) 1.82
Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol (2009) 1.75
The role of Src in prostate cancer. Ann Oncol (2007) 1.71
Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther (2006) 1.66
Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res (2009) 1.63
Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat (2008) 1.62
Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells. Mol Carcinog (1998) 1.54
Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res (2009) 1.54
Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro Oncol (2015) 1.53
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther (2009) 1.53
Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res (2008) 1.52
C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res (2003) 1.52
Src continues aging: current and future clinical directions. Clin Cancer Res (2007) 1.50
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist (2008) 1.49
pp60c-src activation in lung adenocarcinoma. Eur J Cancer (2003) 1.49
Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene (2004) 1.48
SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res (2009) 1.47
Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer (2002) 1.43
Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer (2009) 1.38
Tyrosine kinase inhibitors in cancer therapy. Clin Biochem (2004) 1.36
Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proc Natl Acad Sci U S A (2008) 1.28
Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer (2008) 1.27
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Mol Cancer Ther (2009) 1.26
Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells. BMC Biochem (2002) 1.23
Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer (2009) 1.23
Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res (2007) 1.22
FYN is overexpressed in human prostate cancer. BJU Int (2008) 1.22
Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice. Oncogene (1997) 1.20
Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur J Cancer (1992) 1.15
An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). Int J Mol Med (2007) 1.14
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J Transl Med (2008) 1.13
Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett (2009) 1.13
Molecular prognostic markers in pancreatic cancer. Cancer Control (2000) 1.10
Targeting Src signaling in metastatic bone disease. Int J Cancer (2009) 1.07
Elevated activity and expression of Src-family kinases in human breast carcinoma tissue versus matched non-tumor tissue. J Cancer Res Clin Oncol (2001) 1.04
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res (2009) 1.02
Improving the prognosis for patients with glioblastoma: the rationale for targeting Src. J Neurooncol (2009) 0.95
Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia (2008) 0.92
Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia (2008) 0.91
In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines. Oncol Rep (2008) 0.88
Development of transgenic mice that inducibly express an active form of c-Src in the epidermis. Mol Carcinog (2004) 0.87
Multiple roles for Src in a PDGF-stimulated cell. Exp Cell Res (1999) 0.85
Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells: implication of c-Src and its inhibitor. Int J Oncol (2009) 0.84
Dasatinib may also inhibit c-Kit in triple negative breast cancer cell lines. Breast Cancer Res Treat (2007) 0.80
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A (2008) 3.04
Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. J Natl Cancer Inst (2007) 2.24
Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst (2003) 2.16
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol (2004) 2.10
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A (2009) 1.74
Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. J Urol (2003) 1.51
Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther (2003) 1.39
Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst (2006) 1.39
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer (2009) 1.17
Targeting Src signaling in metastatic bone disease. Int J Cancer (2009) 1.07
Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. BJU Int (2011) 0.99
TAD: a web interface and database for tissue microarrays. Appl Bioinformatics (2002) 0.95
The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. Curr Med Res Opin (2007) 0.89
Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol (2005) 0.89
Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev (2005) 0.89
Expression of hedgehog pathway components in prostate carcinoma microenvironment: shifting the balance towards autocrine signalling. Histopathology (2011) 0.89
Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1. J Biol Chem (2002) 0.88
Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Cancer Lett (2002) 0.87
Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis. Cancer Biol Ther (2008) 0.85
Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer. BMC Med Genomics (2008) 0.84
How to get the most from microarray data: advice from reverse genomics. BMC Genomics (2014) 0.84
Prognostic factors for survival among Caucasian, African-American and Hispanic men with androgen-independent prostate cancer. J Natl Med Assoc (2004) 0.83
Prostate cancer: combination of vaccine plus ipilimumab--safety and toxicity. Nat Rev Urol (2012) 0.81
Genes with a large intronic burden show greater evolutionary conservation on the protein level. BMC Evol Biol (2014) 0.81
Combined laser capture microdissection and serial analysis of gene expression from human tissue samples. Mod Pathol (2005) 0.80
5α-Reductase inhibitors for prostate-cancer prevention. N Engl J Med (2011) 0.76
Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst (2003) 0.75